Sorafenib reverses histone modifications related to EMT in lung carcinoma cells (Zhang et al., 2013), and mocetinostat is a histone deacetylase (HDAC) inhibitor able to reverse the EMT phenotype and sensitize resistant PCa cells to docetaxel by restoring miR‐203 expression and promoting ZEB1 inhibition (Meidhof et al., 2015). This evidence concerns the gene ZEB1 and posterior cortical atrophy.